Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation ...
Edward M. Kaye, MD, CEO and Director of Stoke Therapeutics. For decades, Adrian Krainer, professor at Cold Spring Harbor Laboratory (CSHL), has studied the mechanisms of RNA splicing, how they go awry ...
Korro Bio is a biotech company focused on developing RNA editing technology to treat genetic conditions, specifically alpha-1 antitrypsin deficiency. Their most advanced program, KRRO-110, aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback